Geron Stock

Geron EBIT

The EBIT of Geron (GERN) as of Jul 26, 2026 is -53.13 M USD. In the previous year, EBIT was -173.73 M USD — a change of -69.42% (higher).

EBIT

-53.13 MUSD

YoY

-69.42%

Last updated:

In 2026, Geron's EBIT was -53.13 M USD, a -69.42% increase from the -173.73 M USD EBIT recorded in the previous year.

The Geron EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2020
-76.91 base
Jan 1, 2021
-112.90 base
Jan 1, 2022
-137.55 base
Jan 1, 2023
-193.94 base
Jan 1, 2024
-173.73 base
Jan 1, 2025
-53.13 base
Jan 1, 2026 (e)
-21.89 base
Jan 1, 2027 (e)
40.11 base
YEAREBIT (M USD)
2027 est 40.11
2026 est -21.89
2025 -53.13
2024 -173.73
2023 -193.94
2022 -137.55
2021 -112.90
2020 -76.91
2019 -72.51
2018 -31.07
2017 -29.26
2016 -30.65
2015 -0.56
2014 -36.31
2013 -38.96
2012 -71.76
2011 -96.12
2010 -111.17
2009 -70.23
2008 -67.04
2007 -62.84
2006 -47.36
Access this data via the Eulerpool API

Geron Revenue

Geron Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
253,000.00 USD
-76.91 M USD
-75.62 M USD
Jan 1, 2021
1.39 M USD
-112.90 M USD
-116.11 M USD
Jan 1, 2022
596,000.00 USD
-137.55 M USD
-141.90 M USD
Jan 1, 2023
237,000.00 USD
-193.94 M USD
-184.13 M USD
Jan 1, 2024
76.99 M USD
-173.73 M USD
-174.57 M USD
Jan 1, 2025
183.88 M USD
-53.13 M USD
-85.78 M USD
Jan 1, 2026 (e)
233.82 M USD
-21.89 M USD
-12.77 M USD
Jan 1, 2027 (e)
333.14 M USD
40.11 M USD
38.30 M USD

Geron Margins

Geron stock margins

The Geron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Geron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Geron.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-19,683.40 %
-30,400.40 %
-29,888.14 %
Jan 1, 2021
100.00 %
-8,104.74 %
-8,335.39 %
Jan 1, 2022
100.00 %
-23,078.52 %
-23,808.89 %
Jan 1, 2023
100.00 %
-81,832.91 %
-77,690.72 %
Jan 1, 2024
98.37 %
-225.64 %
-226.73 %
Jan 1, 2025
97.42 %
-28.89 %
-46.65 %
Jan 1, 2026 (e)
97.42 %
-9.36 %
-5.46 %
Jan 1, 2027 (e)
97.42 %
12.04 %
11.50 %

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Geron's EBIT

Geron's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Geron's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Geron's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Geron’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Geron stock

EBIT of Geron is -53.13 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Geron

All Key Metrics — Geron